Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1428-1436

  Grob, Jean Jacques ^a   Amonkar, M M ^b   Martin Algarra, S ^c   Demidov, L V ^d   Goodman, V ^b   Grotzinger, K ^b   Haney, P ^b   Kampgen E ^e   Karaszewska, B ^f   Mauch, C ^g   Miller, Jr ^h   Millward, M ⁱ   Mirakhur, B ^b   Rutkowski, P ^j   Chiarion Sileni, V ^k   Swann, S ^b   Hauschild, A ^l  

^a AIX MARSEILLE UNIVERSITY   (France)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f Przychodnia Lekarska KOMED   (Poland)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j INSTITUTE OF ONCOLOGY   (Poland)

^k VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

BRAF; Chemotherapy; Dabrafenib; Melanoma; Quality of life

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; DACARBAZINE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; OXIME;

ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DYSPNEA; EMOTIONAL STABILITY; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FOLLOW UP; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOCIAL INTERACTION; CLINICAL TRIAL; MELANOMA; METASTASIS; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; DACARBAZINE; HUMANS; IMIDAZOLES; MELANOMA; NEOPLASM METASTASIS; OXIMES; QUALITY OF LIFE;

EID: 84903741191     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu154     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F et al. (eds) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase no. 10 (Updated December 2010). Lyon, France: International Agency for Research on Cancer 2010.
2. Styperek A, Kimball AB. Malignant melanoma: the implications of cost for stakeholder innovation. Am J Pharm Benefits 2012; 4: 66-76.
3. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
4. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
5. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
6. Hauschild A, Grob JJ, Demidov LV et al. An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol 2013; 31 (suppl); abstr 9013.
7. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
8. Cornish D, Holterhues C, van de Poll-Franse LV et al. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol 2009; 20(suppl 6):vi51-vi58.
9. European organisation for research and treatment of cancer: EORTC quality of life questionnaire (EORTC QLQ-C30); http://groups.eortc.be/qol/eortc-qlq-c30 (24 April 2014, date last accessed).
10. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
11. Osoba D, Aaronson N, Zee B et al. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 1997; 6: 103-108.
12. Osoba D, Zee B, Pater J et al. Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353-364.
13. Hjermstad MJ, Fossa SD, Bjordal K et al. Test/retest study of the European Organization for Research and Treatment of Cancer core quality-of-life questionnaire. J Clin Oncol 1995; 13: 1249-1254.
14. Kaasa S, Bjordal K, Aaronson N et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 2260-2263.
15. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144.
16. Scott NW, Fayers PM, Aaronson NK et al. EORTC QLQ-C30 Reference Values. Brussels, Belgium: EORTC Publications 2008.
17. Al-Shakhli H, Harcourt D, Kenealy J. Psychological distress surrounding diagnosis of malignant and nonmalignant skin lesions at a pigmented lesion clinic. J Plast Reconstr Aesthet Surg 2006; 59: 479-486.
18. Newton-Bishop JA, Nolan C, Turner F et al. A quality-of-life study in high-risk (thickness >= or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc 2004; 9: 152-159.
19. Peppercorn JM, Smith TJ, Helft PR et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011; 29: 755-760.
20. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol 2012; 30: 1030-1033.
21. Schadendorf D, Milhem M, Demidov LV et al. Trametinib (T) vs chemotherapy (C) in patients with BRAF V600E+ metastatic melanoma (MM): quality of life (QOL) analysis. Pigment Cell Melanoma Res 2013; 26:154.
22. Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 2003; 21: 821-829.
23. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-1125.
24. Kotapati S, Francis S, Sherrill B. Health related quality of life (HRQL) of patients receiving ipilimumab with dacarbazine as first-line treatment for unresectable stage III/IV melanoma. Pigment Cell Melanoma Res 2011; 24(5): 1037.
25. Revicki DA, van den Eertwegh AJ, Lorigan P et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes 2012; 10: 66.
26. Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 1997; 16: 1197-1209.